Nanexa AB today announces that the company has received a decision from Finansinspektionen (Sweden's financial supervisory authority) to pay a penalty fee of SEK 1,000,000 regarding events that occurred in 2017.

Finansinspektionen has found that Nanexa, in connection with decision regarding a rights issue in September 2017, has disregarded the requirements for publication of insider information and preparation of a correct insider list in Regulation (EU) 596/2014 of the European Parliament and of the Council on market abuse (market abuse regulation).

A total fee of SEK 1,100,000 has been reduced to SEK 1,000,000 in a proportionality assessment and after Finansinspektionen has established that there has been an unreasonable delay in the handling of the case.
 

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
Erik Penser Bank is the company’s Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with several pharma companies, among others AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

Nanexa receives decision on sanction fee from Finansinspektionen regarding case from 2017

© Modular Finance, source Nordic Press Releases